Health Care [ 9/12 ] | Biotechnology [ 61/74 ]
NASDAQ | Common Stock
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States.
Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis.
The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 18, 25 | -0.12 Increased by +29.41% | -0.15 Increased by +18.42% |
| Nov 4, 24 | -0.17 Decreased by -70.00% | -0.15 Decreased by -13.33% |
| Aug 6, 24 | -0.13 Decreased by -18.18% | -0.14 Increased by +7.14% |
| May 7, 24 | -0.14 Increased by 0.00% | -0.17 Increased by +17.65% |
| Feb 20, 24 | -0.17 Decreased by -70.00% | -0.13 Decreased by -30.77% |
| Nov 2, 23 | -0.10 Decreased by -225.00% | -0.13 Increased by +23.08% |
| Aug 3, 23 | -0.11 Decreased by -450.00% | -0.13 Increased by +15.38% |
| May 4, 23 | -0.14 Decreased by -125.93% | -0.14 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 5.05 M Decreased by -44.98% | -34.21 M Increased by +27.44% | Decreased by -677.43% Decreased by -31.88% |
| Sep 30, 24 | 6.51 M Decreased by -1.39% | -51.11 M Decreased by -78.63% | Decreased by -785.42% Decreased by -81.16% |
| Jun 30, 24 | 7.32 M Decreased by -27.18% | -36.93 M Decreased by -20.97% | Decreased by -504.30% Decreased by -66.12% |
| Mar 31, 24 | 9.95 M Decreased by -18.36% | -40.61 M Decreased by -1.25% | Decreased by -407.98% Decreased by -24.01% |
| Dec 31, 23 | 9.18 M Decreased by -57.40% | -47.15 M Decreased by -57.73% | Decreased by -513.67% Decreased by -270.22% |
| Sep 30, 23 | 6.60 M Decreased by -93.49% | -28.61 M Decreased by -207.46% | Decreased by -433.55% Decreased by -1.75 K% |
| Jun 30, 23 | 10.06 M Decreased by -78.10% | -30.53 M Decreased by -349.93% | Decreased by -303.58% Decreased by -1.95 K% |
| Mar 31, 23 | 12.19 M Decreased by -96.15% | -40.11 M Decreased by -123.79% | Decreased by -328.99% Decreased by -717.84% |